Gene · 1723
DHODH: dihydroorotate dehydrogenase (quinone)
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DHODH: dihydroorotate dehydrogenase (quinone). Genes, record 1723. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1723
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q02127 | Dihydroorotate dehydrogenase (quinone), mitochondrial | 395 | 105 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 43785 | Q02127 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1256 | Q02127 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1256 | Q02127 | Espacenet |
| EP 4541812 A2 | 2025-04-23 | 4 | Q02127 | Espacenet |
| US 12203103 B2 | 2025-01-21 | 4 | Q02127 | Espacenet |
| JP 2023544267 A | 2023-10-23 | 32 | Q02127 | Espacenet |
| KR 1020230068401 A | 2023-05-17 | 4 | Q02127 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 24389 | Q02127 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 2351 | Q02127 | Espacenet |
| US 11401555 B2 | 2022-08-02 | 100 | Q02127 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASLAN-003 | CHEMBL2263632 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
| BREQUINAR | CHEMBL38434 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
| EMVODODSTAT | CHEMBL4650336 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
| LEFLUNOMIDE | CHEMBL960 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
| TERIFLUNOMIDE | CHEMBL973 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
| VIDOFLUDIMUS | CHEMBL197194 | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | ChEMBL |
Trials132
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07388407 | LEFLUNOMIDE | ClinicalTrials.gov | ||
| NCT07388407 | TERIFLUNOMIDE | ClinicalTrials.gov | ||
| NCT07189325 | TERIFLUNOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06923488 | LEFLUNOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06540937 | LEFLUNOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06454383 | LEFLUNOMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT06229340 | LEFLUNOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06190145 | TERIFLUNOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06176911 | TERIFLUNOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06141473 | TERIFLUNOMIDE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 132
See all 132 trialsNIH grants1,473
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DHODH papers | Newest fiscal year |
|---|---|---|---|
| R01AI103947 | Lead Optimization of DHODH Inhibitors for Malaria | 16 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| R01AI109023 | Defining P. falciparum resistance to artemisinin-based combination therapies | 10 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 7 | 2025 |
| R01AI124678 | Elucidating the molecular basis of piperaquine resistance in Plasmodium falciparum | 7 | 2025 |
| P30CA006516 | Dana-Farber/Harvard Cancer Center | 6 | 2025 |
| R01AI028398 | Mitochondrial Functions in Malaria Parasites | 6 | 2025 |
| R37AI050234 | Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug Resistance | 6 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 5 | 2025 |
1 to 10 of 1,473Source NIH's project files
See all 1,473 nih grantsPapers2,016
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond. | JACS Au | 2026 | 42819300 | PubTator, text mining | PubMed |
| Structural insights into DHODH-mediated catalysis and drug resistance. | bioRxiv | 2026 | 42818329 | PubTator, text mining | PubMed |
| NRF2-Regulated Ferroptosis in Breast Cancer: Mechanisms, Resistance, and Therapeutic Opportunities. | Asia Pac J Clin Oncol | 2026 | 42802387 | PubTator, text mining | PubMed |
| Pharmacological targeting of ferroptosis in cancer: mechanisms, tumor immunity, and translational challenges. | Pharmacol Rep | 2026 | 42789241 | PubTator, text mining | PubMed |
| Programmed cell death evasion in BRAF V600E-driven primary CNS tumors and thyroid cancer brain metastases. | Front Neurol | 2026 | 42769885 | PubTator, text mining | PubMed |
| DHODH inhibition drives albumin-mediated drug resistance through TERF2IP lactylation-activated macropinosome-mitochondria contact. | Nat Commun | 2026 | 42736281 | PubTator, text mining | PubMed |
| Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma. | Transl Res | 2026 | 42732873 | PubTator, text mining | PubMed |
| The redox paradox in neurological disorders: balancing cytoprotection, ferroptosis, and therapeutic targeting. | Brain Res | 2026 | 42700879 | PubTator, text mining | PubMed |
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | 42673947 | PubTator, text mining | PubMed |
| Network pharmacology based identification of potential phytocompounds from Betula utilis in the treatment of leishmaniasis. | J Parasit Dis | 2026 | 42670328 | PubTator, text mining | PubMed |
1 to 10 of 2,016
See all 2,016 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1723
GET https://conductscience.org/api/genes/v1/1723/patents?page=2